DuPont is to form a joint venture with Dutch life sciences and materials sciences company Royal DSM to develop, manufacture and commercialize advanced surgical biomedical materials.
DuPont and DSM will each own a 50 percent interest in the venture, to be called Actamax Surgical Materials LLC.